Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Sovereign Pharmaceuticals, LLC
WARNING LETTER
•Sovereign Pharmaceuticals, LLC•April 22, 2022

Sovereign Pharmaceuticals, LLC – FDA Warning Letter, Apr 22, 2022

Record Details

The FDA issued a Warning Letter to Sovereign Pharmaceuticals, LLC, following an inspection from April 13-22, 2022, identifying significant Current Good Manufacturing Practice (CGMP) violations for finished pharmaceuticals, rendering their drug products adulterated. The company manufactures bulk tablets for (b)(4), which are unapproved drugs and biological products.

Key violations include: 1. **Failure to establish adequate written procedures for production and process control (21 CFR 211.100(a)):** The firm failed to validate manufacturing processes for bulk (b)(4) tablets, with multiple out-of-specification (OOS) results for active ingredients, tablet assay, and weight during process performance qualification (PPQ). The company's response was deemed inadequate, lacking sufficient data to show process variability and an ongoing program for monitoring process control. 2. **Failure to thoroughly investigate unexplained discrepancies or batch failures (21 CFR 211.192):** Approximately 27 validation and commercial batches of (b)(4) tablets with OOS blend powder drum assay results were compressed and released without adequate investigation. The firm's investigation was deficient, not extending to all similarly impacted products and failing to assess other sources of variability. 3. **Failure of the quality control unit to establish and follow written procedures (21 CFR 211.22(d)):** The Quality Unit (QU) failed to adequately

Company
Sovereign Pharmaceuticals, LLC
Inspection date
April 22, 2022
Product type
Drugs
Office
Office of Pharmaceutical Quality Operations Division I
Person
  • Tamala P. Bogan (Director of Investigations Branch)
View Company Profile

ID · 56437b1f-b184-4771-8dc3-b324b567f1ab

Violation Codes10
21 U.S.C. 321(g)21 CFR 21021 CFR 21121 U.S.C. 360(j)21 CFR 20721 U.S.C. 331(p)21 U.S.C. 352(o)21 CFR 211.100(a)21 CFR 211.19221 CFR 211.22(d)

Full citation text and observation details available on the Dashboard.

Other documents for Sovereign Pharmaceuticals, LLC
  • 483 - 2025-05-12May 12, 2025
  • 483 - 2023-08-02August 2, 2023
  • 483 - 2022-04-22April 22, 2022
  • 483 - 2021-09-01September 1, 2021
  • 483 - 2019-12-12December 12, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Sovereign Pharmaceuticals, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.